Making smart investment decisions in clinical research

Nick Bansback, Edward Keystone, James O'Dell, Ciaran S Phibbs, Keri Hannagan, Mary Brophy, Aslam Anis, Nick Bansback, Edward Keystone, James O'Dell, Ciaran S Phibbs, Keri Hannagan, Mary Brophy, Aslam Anis

Abstract

A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs.

Trial registration: NCT00405275 , registered 29 November 2006.

References

    1. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for Active Rheumatoid Arthritis after Methotrexate Failure. N Engl J Med. 2013;369:307–18. doi: 10.1056/NEJMoa1303006.
    1. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. The Lancet. 2012;379(9827):1712–20. doi: 10.1016/S0140-6736(12)60027-0.
    1. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824–35. doi: 10.1002/art.34498.
    1. Graudal N, Hubeck-Graudal T, Tarp S, Christensen R, Jürgens G. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One. 2014;9:e106408. doi: 10.1371/journal.pone.0106408.
    1. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010;62:2852–63. doi: 10.1002/art.27592.
    1. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;4:CD007848.
    1. Drugs information online. U. S. Pharmaceutical Sales—2013. Top 100 Drugs for 2013 by Sales. 2013. [Available at ] Access date 1 December 2015.
    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39. doi: 10.1002/acr.21641.
    1. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334:1287–91. doi: 10.1056/NEJM199605163342002.
    1. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9. doi: 10.1056/NEJM199901283400401.
    1. Canadian Institute for Health Research: RCT Evaluation Criteria and Headings. [Available at ] Access date 1 December 2015
    1. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheuma. 2002;46:1164–70. doi: 10.1002/art.10228.
    1. Moreland LW. Potential biologic agents for treating rheumatoid arthritis. Rheum Dis Clin N Am. 2001;27:445–91. doi: 10.1016/S0889-857X(05)70212-X.
    1. Myers E, McBroom AJ, Shen L, Posey RE, Gray MR, Sanders GD. Value-of-information analysis for patient-centered outcomes research prioritization. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2012.
    1. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151:203–20. doi: 10.7326/0003-4819-151-3-200908040-00125.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever